Is the combination angiotensin receptor blocker/neprilysin inhibitor poised to change heart failure therapy?

Seth Bilazarian and Chris Cannon discuss the role of ezetimibe in secondary prevention and whether super-low LDL-C levels are the way to go.

Marshall Summar speaks with FDA director of the Office of Orphan Products Development, Gayatri Rao, about progress in diagnostics and therapeutics for rare diseases.

Pregnant women might not appreciate the dangers that influenza poses to them and their unborn children.

A Mayo Clinic roundtable tackles the question of whether statin intolerance is a real phenomenon and the risks of diabetes associated with these lipid-lowering agents.

Paul A. Offit, MD, gives his expert opinion on the new serogroup B meningococcal vaccine and who might benefit most.

CDC describes the 'one-two punch' pneumococcal vaccination of older adults.

A drug that targets the sphingosine-1 receptor results in less new brain damage on MRI in patients with MS.

Samuel Goldhaber describes some sobering findings on anticoagulation adherence from a military healthcare database.

Medscape Editor-in-Chief Eric Topol, MD, talks with FDA Commissioner Margaret Hamburg about the biggest drug-related issues in medicine today.